Executive Brief: Natco Pharma's Strategic US Launch of Pomalidomide

Market Opportunity & Financial Implications Addressable Market: The US market for Pomalidomide capsules is substantial, with estimated sales reaching $3.2 billion for the 12-month period ending September 2025. First-Mover Advantage: Based on US Food and Drug Administration (FDA) data, Natco Pharma anticipates holding 180 days of shared exclusivity. This presents a critical window for capturing market share and generating significant near-term revenue. Distribution Strategy: The capsules will be available in 1mg, 2mg, 3mg, and 4mg strengths and distributed primarily through high-margin specialty pharmacies and clinics. Clinical Profile Pomalidomide is a thalidomide analogue targeting critical oncology and specialty treatment pathways: Multiple Myeloma: Indicated for adult patients who have undergone at least two prior therapies (including lenalidomide and a proteasome inhibitor) and demonstrated disease progression within 60 days of completing their last therapy. Kaposi Sarcoma: Approved for AIDS-related Kaposi sarcoma post-failure of highly active antiretroviral therapy (HAART), as well as for HIV-negative adults with the condition. Strategic Impact According to Vice-Chairman and CEO Rajeev Nannapeneni, this launch is a strategic milestone that significantly fortifies Natco Pharma’s oncology and specialty portfolio in the lucrative US market. From a market perspective, while the stock saw a minor 3.4% correction to ₹955 in the preceding session, it has maintained robust momentum with an 11.6% gain over the past month, reflecting positive broader sentiment.